Intravacc, Versatope to develop universal flu vaccine

By The Science Advisory Board staff writers

June 8, 2020 -- Dutch vaccine developer Intravacc and biotechnology firm Versatope have signed an agreement to collaborate on a universal influenza vaccine.

Intravacc will support Lowell, MA-based Versatope in bringing its universal influenza vaccine candidate VT-105 to clinical trial; the vaccine will include Intravacc's outer membrane vesicles (OMV) technology, the two companies said.

The companies hope that the OMV technology will provide better cross-strain protection than other influenza vaccines that consist of individual strains.

Copyright © 2020

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?